Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Genesys has reported encouraging results of an analysis examining the potential association between immune responses to Gvax immunotherapy for prostate cancer and increased patient survival in a Phase II trial in patients with metastatic, hormone refractory prostate cancer.
Subscribe to our email newsletter
More than 400 patient-specific Gvax-induced antibody responses were identified in the sera of the treated patients by three different biochemical techniques confirming, as previously reported, that Gvax treatment results in a broad, multi-antigen immune response. An ongoing analysis of these Gvax-induced antibody responses has shown that at least two of the antibody responses are associated with patient survival, an association that is independent of the dose and number of treatments administered.
Peter Working, senior vice president of R&D at Cell Genesys, said: “The findings being reported today indicate a potential association between two specific Gvax-induced antibody responses and patient survival, an association consistent with the proposed mechanism of action for this product. We look forward to expanding these findings in a prospective analysis of the sera of patients treated in our two randomized controlled Phase III trials.”